UCP3 and type 2 diabetes mellitus: On the other hand, decreased expression of UCP-3 in high glucose concentrations may impair beta-cell function, implicating that mechanisms that increase UCP-3 expression and/or function are potential therapeutic targets to offset defects of insulin secretion in humans with type-2 diabetes.